February 25, 2005 -- For the third day in the row, biotech made a gain, moving steadily upward throughout the session and closing at its highs. At the end of the day, the Centient Biotech 200 was up by 1.29%, climbing 42 points to close at 3347.15. For the week, the CBT 200 gained 21 points. In today’s article, we look at another IPO failure, this one involving a company called Targacept, positive numbers from a Phase II trial for Genaera, news about an FDA delay for Mylan, an always newsworthy stock, and some solid follow-up numbers from American Pharma Partners. More details...
